title: Current Management Strategies in Breast Cancer by Targeting Key Altered Molecular Players.
abstract: Breast cancer is the second largest disease affecting women worldwide. It remains the most frequently reported and leading cause of death among women in both developed and developing countries. Tamoxifen and raloxifene are commonly used selective estrogen receptor modulators for treatment of breast cancer in women with high risk, although resistance occurs by tamoxifen after 5 years of therapy and both drugs cause uterine cancer and thromboembolic events. Aromatase inhibitors (AIs) are one of the optional modes used for breast cancer treatment. The combination of AIs along with tamoxifen can also be beneficial. Various therapeutic agents from different sources are being studied, which further need to be improved for potential outcome. For this, clinical trials based on large number of patients with optimal dose and lesser side effects have to be more in practice. Despite the clinical trials going on, there is need of better molecular models, which can identify high risk population, new agents with better benefit having less side effects, and improved biomarkers for treating breast cancer.
authors.affiliation: School of Life Science, Jawaharlal Nehru University , New Delhi , India.
authors.forename: Shazia
authors.initials: S
authors.lastname: Ali
authors.affiliation: School of Life Science, Jawaharlal Nehru University , New Delhi , India.
authors.forename: Neelima
authors.initials: N
authors.lastname: Mondal
authors.affiliation: Department of Biochemistry, Faculty of Science, Center of Innovation in Personalized Medicine, King Fahd Center for Medical Research, King Abdulaziz University , Jeddah , Saudi Arabia.
authors.forename: Hani
authors.initials: H
authors.lastname: Choudhry
authors.affiliation: Center of Excellence in Genomic Medicine Research, King Abdulaziz University , Jeddah , Saudi Arabia.
authors.forename: Mahmood
authors.initials: M
authors.lastname: Rasool
authors.affiliation: Center of Excellence in Genomic Medicine Research, King Abdulaziz University , Jeddah , Saudi Arabia.
authors.forename: Peter N
authors.initials: PN
authors.lastname: Pushparaj
authors.affiliation: National Institute of Biologicals , Noida , India.
authors.forename: Mohammad A
authors.initials: MA
authors.lastname: Khan
authors.affiliation: Department of Computer Science, Jamia Millia Islamia , New Delhi , India.
authors.forename: Maryam
authors.initials: M
authors.lastname: Mahfooz
authors.affiliation: Department of Biotechnology, Jamia Millia Islamia , New Delhi , India.
authors.forename: Ghufrana A
authors.initials: GA
authors.lastname: Sami
authors.affiliation: King Fahd Medical Research Center, King Abdulaziz University , Jeddah , Saudi Arabia.
authors.forename: Jummanah
authors.initials: J
authors.lastname: Jarullah
authors.affiliation: King Fahd Medical Research Center, King Abdulaziz University , Jeddah , Saudi Arabia.
authors.forename: Ashraf
authors.initials: A
authors.lastname: Ali
authors.affiliation: King Fahd Medical Research Center, King Abdulaziz University , Jeddah , Saudi Arabia.
authors.forename: Mohammad S
authors.initials: MS
authors.lastname: Jamal
keywords: aromatase inhibitors; biomarker; breast cancer; chemoprevention; epidermal growth factor receptor; estrogen receptor